en sv

Press Releases

The stem cell company NextCell Pharma participates as a reference laboratory in NIBSC study

NextCell Pharma AB (“NextCell”) announces today, that it has acted as a reference laboratory to assist National Institute for Biological Standards and Control (NIBSC) in the development of a reference…

Cellaviva Sverige February 21, 2020

Participates in innovation projects for cell-based products

NextCell Pharma AB (NextCell) a0nnounces they are, in collaboration with Research Institutes of Sweden (RISE) and Your Special Delivery Service, participating in a CAMP organized project titled: ‘Establishing a non-dry…

Cellaviva Sverige February 10, 2020

NextCell to present its progress at Swiss Nordic Bio 2020

NextCell Pharma AB (“NextCell”) presented, in December 2019, efficacy data of ProTrans stem cells in an interim analysis of the ongoing phase I/II trial, ProTrans-1. Patients receiving medium or high…

Cellaviva Sverige February 4, 2020

Interim Report 1 2019/2020

NextCell Pharma AB today publish the Interim Report 1 for the period September 1 – November 30, 2019. “NextCell”, “NXTCL” or “Company” refer to NextCell Pharma AB with organization number…

Cellaviva Sverige January 31, 2020

Extended permission from the Medical Products Agency

NextCell Pharma AB (“NextCell”) announces that they have been granted with an extended wholesale distribution authorization from the Medical Products Agency. In October, the NextCell operation were subject to a…

Cellaviva Sverige December 11, 2019

Promising Results from clinical trial with ProTrans stem cells

NextCell Pharma AB (“NextCell”) announces today that the primary efficacy measures have reached significance in the dose-escalation phase of the company’s clinical trial. After one year follow-up, the six patients…

Cellaviva Sverige December 4, 2019

A part of Vision-driven Health

NextCell Pharma AB (“NextCell”) announces that it is chosen as one of the collaborators in the newly Vinnova funded project Vision-driven Health: Sweden a leader in advanced therapies in 2030….

Cellaviva Sverige November 22, 2019

Correction: Notice to attend the Annual General Meeting

NextCell Pharma AB (“NextCell”) announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. Compared to the press release published this morning, corrections…

Cellaviva Sverige November 7, 2019

Notice to attend the Annual General Meeting

NextCell Pharma AB (“NextCell”) announces that a notice of the Annual General Meeting for the 2018-2019 financial year has been published. The annual general meeting will be held on December…

Cellaviva Sverige November 7, 2019

Year-end report 2018-09-01 - 2019-08-31

Nextcell Pharma AB (“NXTCL”) today announces the year-end report for the 2018/2019 fiscal year (2018-08-31 2019-08-31) Twelve months (2018-09-01 until 2019-08-31) Operating income amounted to SEK 1 964 132 (655 413)….

Cellaviva Sverige October 31, 2019

NextCell invests in the Danish Cellaviva operations with a new Copenhagen office

NextCell Pharma AB (“NextCell”) today announces they are investing for growth in Cellaviva’s Danish operations with the opening of a new Copenhagen office. In October, Cellaviva’s new office was opened…

Cellaviva Sverige October 25, 2019

All patients in ProTrans-Repeat are now treated

NextCell Pharma AB (“NextCell”) announces that another significant milestone has been reached when the last patient, as part of the ProTrans-Repeat active treatment group, today has received their treatment. This…

Cellaviva Sverige October 1, 2019